Abbott's leadership has evolved the company prudently by investing in its own fast-growing medical technologies and by acquiring the right set of devices in the most promising areas of healthcare. The result: A global player with the richest pipeline of new offerings in its recent history, and investors are noticing. The drivers behind the forecasted revenue growth of 6.5-7.5 percent this year include contributions from all Abbott businesses, said Brian Yoor, chief financial officer and executive vice president, at a Barclays investor conference. Abbott's FreeStyle Libre continuous glucose monitoring system, its Alinity diagnostics platforms and its fast-growing Mitraclip treatment to repair heart valves are just some of the technologies that are making a big impact. 'It's just an exciting time for Abbott, and it's exciting to have clear line of sight of where we're going and how we're getting there,' Yoor said.